High dose bolus IL-2 is approved by the FDA to treat renal carcinoma and melanoma, while low dose IL-2 therapies are currently tested in patients suffering from chronic graft-versus host disease (GVHD) or diabetes [9,10,12]. Here, IL2 is linked to graft versus host disease.